181 filings
Page 3 of 10
DEFA14A
qcw vz60si3lsta
30 Jun 22
Additional proxy soliciting materials
7:15am
S-8
tqxcy02g
8 Jun 22
Registration of securities for employees
4:01pm
8-K
l9wazi mehzo2ygr6
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
2f86yn 3kxlaen6
30 Mar 22
Regulation FD Disclosure
7:44am
8-K
f1b20g eh
4 Feb 22
Company Ended the Quarter With Cash of Approximately $527.0 Million
7:09am
S-8
t4ysx
10 Jan 22
Registration of securities for employees
4:31pm
8-K
wdssiaov f2
7 Jan 22
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
3:57pm
8-K
h3n qrgfz
5 Jan 22
Regulation FD Disclosure
7:38am
8-K
v5v87ne 5p
30 Dec 21
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
7:05am
8-K
do7dzndumjkjjryc65fl
23 Nov 21
Entry into a Material Definitive Agreement
4:27pm
8-K
n2zqlsqki b5532j
17 Nov 21
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
8:36am
8-K
5k1qcv
5 Nov 21
Company Ended the Quarter With Cash of Approximately $559 Million
7:39am
8-K
q4eh8fbkr9s 7y
27 Sep 21
Immunovant to Participate in Roivant R&D Day 2021
8:23am
8-K
1f9biasa
15 Sep 21
Immunovant Appoints Renee Barnett as Chief Financial Officer
7:23am